NewEdge Advisors’s iBio IBIO Stock Holding History

NewEdge Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20	Closed	-$11K	–	1073
2020 Q4	$11K	Hold	20	–	–	﹤0.01%	972
2020 Q3	$20K	Buy	+20	New	+$29K	﹤0.01%	910

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

NewEdge Advisors's IBIO Position: Q1 2021 in Review

NewEdge Advisors sold out of iBio (IBIO) in Q1 2021, closing a stake of 20 shares — an estimated $11K sold.

NewEdge Advisors first reported a position in IBIO in Q3 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 91 funds tracked by Wall St. Rank hold IBIO as of Q1 2021.

NewEdge Advisors reported no remaining iBio position as of Q1 2021 after selling out during the quarter.
NewEdge Advisors sold 20 iBio shares in Q1 2021, an estimated $11K.
NewEdge Advisors first reported a position in iBio in Q3 2020 and held it in 2 quarters.
NewEdge Advisors's iBio position peaked at $20K in Q3 2020.
91 funds tracked by Wall St. Rank held iBio as of Q1 2021.

Based on NewEdge Advisors's 13F filing for Q1 2021, filed 26 Apr 2021.